The "Tricky Business" of Identifying Mechanisms of Resistance to Anti-PD-1.
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 28468948.
- Also identified by DOI 10.1158/1078-0432.CCR-17-0669.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Resistance to immune checkpoint inhibitors can vary between patients and among metastases. Understanding the genomic, transcriptomic, and microenvironmental factors that contribute to this variability will reveal the mechanisms that tumors utilize to evade the therapeutic effects of checkpoint inhibitor immunotherapies and will enable us to develop strategies to overcome them. <i>Clin Cancer Res; 23(12); 2921-3. ©2017 AACR</i><i>See related article by Ascierto et al., p. 3168</i>.
Medical subject headings
- Drug Resistance, Neoplasm
- Neoplasms
- Programmed Cell Death 1 Receptor